Protocol Deviations Start Earlier Than You Think
July 21, 2026
Most sponsors associate protocol deviations with events that occur later in a clinical trial, like missed visits or incomplete documentation.
In reality, one of the earliest and most consequential protocol deviations is happening during patient randomization.
Randomization is often perceived as a simple operational step:
patient enrolled, button clicked, treatment assigned.
But under the pressure of busy clinical sites, even small mistakes can have significant consequences.
And the price sponsors pay is really high:
- treatment may be assigned incorrectly
- investigational product inventory is affected
- study drug is dispensed unnecessarily
In some cases, it may even compromise the integrity of the study population.
Protecting your study integrity begins by building processes that consistently prevent these errors from happening in the first place. And this is where a well-designed RTSM comes to the scene as a safeguard for protocol compliance.
Why Modern RTSM Matters
Instead of relying on users to remember every study-specific requirement, the system consistently follows the configured randomization algorithm and eligibility logic.
- Only patients who meet the predefined study criteria proceed to randomization.
- Treatment allocation follows the protocol-defined randomization scheme without introducing investigator bias.
- The system automatically assigns the correct investigational product kit while preserving study blinding throughout the process.
Every action is recorded, traceable, and performed consistently across all participating sites.
It does not replace clinical judgment, but ensures that operational execution remains consistent every single time.
Delivering this level of consistency requires far more than implementing a randomization algorithm.
Built to Protect Study Integrity – Not Just Randomize Patients
At Flex Databases, we believe an RTSM should do far more than assign patients to treatment groups. It should orchestrate the entire randomization and investigational product workflow while protecting data integrity, protocol compliance, and study blinding at every step.
The process begins with study teams configuring the randomization scheme, treatment arms, inventory strategy, and supply rules. Once validated, this logic is automatically applied throughout the study.
For site users, the workflow is simple. After confirming patient eligibility, they initiate randomization with a single click. Flex RTSM:
- automatically assigns the patient according to the predefined lists
- allocates the correct investigational product kit
- supports kit replacement without compromising study blinding
- updates inventory
- triggers site resupply when predefined levels are reached
As part of the unified Flex Databases eClinical platform, RTSM is directly integrated with EDC, eliminating duplicate data entry and maintaining a single source of truth for patient assignment, treatment allocation, and drug supply. Every action is automatically recorded in a complete audit trail, helping sponsors maintain protocol compliance while reducing operational risk throughout the study lifecycle.
A modern RTSM creates value not by making randomization faster, but by making every randomization correct, compliant, and fully traceable.
